Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, Kim S, Duru V, Bouchier C, Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor MC, Bout DM, Ménard S, Rogers OW, Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale J-C, Fairhurst RM, Benoit-Vical F, Mercereau-Puijalon O, Ménard D (2014). A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505(7481):50-55.
Crossref

Ashley AE, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B, Sopha C, Chuor CM, Nguon C, Sovannaroth S, Pukrittayakamee S, Jittamala P, Chotivanich K, Chutasmit K, Suchatsoonthorn C, Runcharoen R, Hien TT, Thuy-Nhien NT, Thanh NV, Phu NH, Htut Y, Han K-T, Aye KH, Mokuolu OA, Olaosebikan RR, Folaranmi OO, Mayxay M, Khanthavong M, Hongvanthong B, Newton PN, Onyamboko MA, Fanello CI, Tshefu AK, Mishra N, Valecha N, Phyo AP, Nosten F, Yi P, Tripura R, Borrmann S, Bashraheil M, Peshu J, Faiz MA, Ghose A, Hossain MA, Samad R, Rahman MR, Hasan MM, Islam A, Miotto O, Amato R, MacInnis B, Stalker J, Kwiatkowski DP, Bozdech Z, Jeeyapant A, Cheah PY, Sakulthaew T, Chalk J, Intharabut B, Silamut K, Lee SJ, Vihokhern B, Kunasol C, Imwong M, Tarning J, Taylor WJ, Yeung S, Woodrow CJ, Flegg JA, Das D, Smith J, Venkatesan M, Plowe CV, Stepniewska K, Guerin PJ, Dondorp AM, Day NP, White NJ (2014). Spread of artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 371(5):411-23.
Crossref

Ashley EA, Krudsood S, Phaiphun L, Srivilairit S, McGready R, Leowattana W, Hutagalung R, Wilairatana P, Brockman A, Looareesuwan S, Nosten F, White NJ (2004). Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. J. Infect. Dis. 190(10):1773-82.
Crossref

Bacon JD, Latour C, Lucas C, Colina O, Ringwald P, Picot S (2007). Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates. Antimicrob. Agents Chemother. 51(4):1172-1178.
Crossref

Brasseur P, Agnamey P, Gaye O, Cisse M, Badiane M, Vaillant M, Taylor WRJ, Olliaro P (2009). Dosing accuracy of artesunate and amodiaquine as treatment for falciparum malaria in Casamance, Senegal. Trop. Med. Int. Health 14(1):79-87.
Crossref

Chanda P, Hawela M, Kango M, Sipilanyambe N (2006). Assessment of the therapeutic efficacy of a paediatric formulation of artemether-lumefantrine (Coartesiane) for the treatment of uncomplicated Plasmodium falciparum in children in Zambia. Malar. J. 5:75.
Crossref

Cheruiyot AC, Auschwitz JM, Lee PJ, Yeda RA, Okello CO, Leed SE, Talwar M, Murthy T, Gaona HW, Hickman MR, Akala HM, Kamau E, Johnson JD (2016). Assessment of the Worldwide antimalarial resistance network standardized procedure for in vitro malaria drug sensitivity testing using SYBR green assay for field samples with various initial parasitemia levels. Antimicrob. Agents Chemother. 60(4):2417-2424.
Crossref

Denis MB, Davis TME, Hewitt S, Incardona S, Nimol K, Fandeur T, Poravuth Y, Lim C, Socheat D (2002). Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin. Infect. Dis. 35(12):1469-1476.
Crossref

Desjardins RE, Canfield CJ, Haynes JD, Chulay JD (1979). Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. 16(6):710-718.
Crossref

Djallé D, Njuimo SP, Manirakiza A, Laganier R, Le Faou A, Rogier C (2014). Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: a randomized trial. Malar. J. 13(9):1475-2875.
Crossref

Djimdé AA, Fofana B, Sagara I, Sidibe B, Toure S, Dembele D, Dama S, Ouologuem D, Doumbo OK (2008). Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Am. J. Trop. Med. Hyg. 78(3):455-461.

Dondorp AM, Nosten F, Yi P, Das D, Hanpithakpong W, Lee SJW, Ringwald P, Imwong M, Chotivanich K, Lim P (2012). Artemisinin Resistance in Plasmodium falciparum Malaria. N. Engl. J. Med. 361(5):455-467.
Crossref

Dondorp MA, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NPJ, Lindegardh N, Socheat D, White NJ (2009). Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 361(5): 455-67.
Crossref

Duah NO, Matrevi SA, de Souza DK, Binnah DD, Tamakloe MM, Opoku VS, Onwona CO, Narh CA, Quashie NB, Abuaku B, Duplessis C, Kronmann KC, Koram KA (2013). Increased pfmdr1 gene copy number and the decline in pfcrt and pfmdr1 resistance alleles in Ghanaian Plasmodium falciparum isolates after the change of anti-malarial drug treatment policy. Malar. J. 12:377.
Crossref

Espié E, Lima A, Atua B, Dhorda M, Flévaud L, Sompwe EM, Palma Urrutia PP, Guerin PJ (2012). Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood Plasmodium falciparum malaria in Democratic Republic of Congo: a randomized non-inferiority trial. Malar. J. 11(1):174.
Crossref

Ezzet F, Karbwang J (1998). Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Br. J. Clin. Pharmacol. 46(6):553-561.
Crossref

Fall B, Diawara S, Sow K, Baret E, Diatta B, Fall KB, Mbaye PS, Fall F, Diémé Y, Rogier C, Wade B, Bercion R, Pradines B (2011). Ex vivo susceptibility of Plasmodium falciparum isolates from Dakar, Senegal, to seven standard anti-malarial drugs. Malar. J. 10(1):310.
Crossref

Graz B, Willcox ML, Diakite C, Falquet J, Dackuo F, Sidibe O, Giani S, Diallo D (2010). Argemone mexicana decoction versus artesunate-amodiaquine for the management of malaria in Mali: policy and public-health implications. Trans. R. Soc. Trop. Med. Hyg. 104(1):33-41.
Crossref

Issaka M, Salissou A, Arzika I, Guillebaud J, Maazou A, Specht S, Zamanka H, Fandeur T (2013). Ex Vivo responses of Plasmodium falciparum clinical isolates to conventional and new antimalarial drugs in niger. Antimicrob. Agents Chemother. 57(7):3415-3419.
Crossref

Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, Ekala TM, Bouchier C, Esterre P, Fandeur T, Mercereau-Puijalon O (2005). Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 366(9501):1960-1963.
Crossref

Kaddouri H, Djimdé A, Dama S, Kodio A, Tekete M, Hubert V, Koné A, Maiga H, Yattara O, Fofana B, Sidibe B, Sangaré OPC, Doumbo O, Le Bras J (2008). Baseline in vitro efficacy of ACT component drugs on Plasmodium falciparum clinical isolates from Mali. Int. J. Parasitol. 38(7):791-798.
Crossref

Kamau E, Campino S, Amenga-Etego L, Drury E, Ishengoma D, Johnson K, Mumba D, Kekre M, Yavo W, Mead D, Bouyou-Akotet M, Apinjoh T, Golassa L, Randrianarivelojosia M, Andagalu B, Maiga-Ascofare O, Amambua-Ngwa A, Tindana P, Ghansah A, MacInnis B, Kwiatkowski D, Djimde AA (2015). K13-Propeller Polymorphisms in Plasmodium falciparum parasites from Sub-Saharan Africa. J. Infect. Dis. 211(8):1352-5.

Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke SG, Talisuna AO, Greenhouse B, Nosten F, Rosenthal PJ, Wabwire-Mangen F, Dorsey G (2007). Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: A randomized trial. PLoS Clin. Trials 2(5):e20.
Crossref

Kaye DK, Nshemerirwe R, Mutyaba TS, Ndeezi G (2008). A randomized clinical trial comparing safety, clinical and parasitological response to artemether-lumefantrine and chlorproguanil-dapsone in treatment of uncomplicated malaria in pregnancy in Mulago hospital, Uganda. J. Infect. Dev. Count. 2(2):135-139.
Crossref

Leang R, Taylor WRJ, Bouth DM, Song L, Tarning J, Char MC, Kim S, Witkowski B, Duru V, Domergue A, Khim N, Ringwald P, Menard D (2015). Evidence of plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in Western Cambodia: Dihydroartemisinin-piperaquine open-label multicenter clinical assessment. Antimicrob. Agents Chemother. 59(8):4719-4726.
Crossref

Lim P, Alker AP, Khim N, Shah NK, Incardona S, Doung S, Yi P, Mey Bouth D, Bouchier C, Mercereau Puijalon O, Meshnick SR, Wongsrichanalai C, Fandeur T, Le Bras J, Ringwald P, Ariey F (2009). Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar. J. 8(1):11.
Crossref

Lim P, Dek D, Try V, Eastman RT, Chy S, Sreng S, Suon S, Mao S, Sopha C, Sam B, Ashley EA, Miotto O, Dondorp AM, White NJ, Su XZ, Char MC, Anderson JM, Amaratunga C, Menard D, Fairhurst RM (2013). Ex Vivo Susceptibility of Plasmodium falciparum to antimalarial drugs in western, Northern, and Eastern Cambodia, 2011-2012: Association with molecular markers. Antimicrob. Agents Chemother. 57(11):5277-5283.
Crossref

Lim P, Wongsrichanalai C, Chim P, Khim N, Kim S, Chy S, Sem R, Nhem S, Yi P, Duong S, Bouth DM, Genton B, Beck HP, Gobert JG, Rogers WO, Coppee JY, Fandeur T, Mercereau-Puijalon O, Ringwald P, Le Bras J, Ariey F (2010). Decreased in vitro susceptibility of plasmodium falciparum isolates to artesunate, mefloquine, chloroquine, and quinine in Cambodia from 2001 to 2007. Antimicrob. Agents Chemother. 54(5):2135-2142.
Crossref

Lobo E, de Sousa B, Rosa S, Figueiredo P, Lobo L, Pateira S, Fernandes N, Nogueira F (2014). Prevalence of pfmdr1 alleles associated with artemether-lumefantrine tolerance/resistance in Maputo before and after the implementation of artemisinin-based combination therapy. Malar. J. 13:300.
Crossref

Marquino W, Huilca M, Calampa C, Falconi E, Cabezas C, Naupay R, Ruebush 2nd TK (2003). Efficacy of mefloquine and a mefloquine-artesunate combination therapy for the treatment of uncomplicated Plasmodium falciparum malaria in the Amazon Basin of Peru. Am. J. Trop. Med. Hyg. 68(5):608-612.

Mårtensson A, Strömberg J, Sisowath C, Msellem MI, Gil JP, Montgomery SM, Olliaro P, Ali AS, Björkman A (2005). Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin. Infect. Dis. 41:1079-1086.
Crossref

Mayxay M, Khanthavong M, Lindegårdh N, Keola S, Barends M, Pongvongsa T, Yapom R, Annerberg A, Phompida S, Phetsouvanh R, White NJ, Newton PN (2004). Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic. Clin. Infect. Dis. 39(8):1139-47.
Crossref

Mbengue A, Bhattacharjee S, Pandharkar T, Liu H, Estiu G, Stahelin RV, Rizk SS, Njimoh DL, Ryan Y, Chotivanich K, Nguon C, Ghorbal M, Lopez-Rubio J-J, Pfrender M, Emrich S, Mohandas N, Dondorp MA, Wiest O, Haldar K (2015). A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature 520(7549):683-687.
Crossref

Miotto O, Amato R, Ashley EA, MacInnis B, Almagro-Garcia J, Amaratunga C, Lim P, Mead D, Oyola SO, Dhorda M, Imwong M, Woodrow C, Manske M, Stalker J, Drury E, Campino S, Amenga-Etego L, Thanh TN, Tran HT, Ringwald P, Bethell D, Nosten F, Phyo AP, Pukrittayakamee S, Chotivanich K, Chuor CM, Nguon C, Suon S, Sreng S, Newton PN, Mayxay M, Khanthavong M, Hongvanthong B, Htut Y, Han KT, Kyaw MP, Faiz MA, Fanello CI, Onyamboko M, Mokuolu OA, Jacob CG, Takala-Harrison S, Plowe CV, Day NP, Dondorp AM, Spencer CC, McVean G, Fairhurst RM, White NJ, Kwiatkowski DP (2015). Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nat. Genet. 47(3):226-34.
Crossref

Mita T, Tachibana SI, Hashimoto M, Hirai M (2016). Plasmodium falciparum kelch 13: a potential molecular marker for tackling artemisinin-resistant malaria parasites. Exp. Rev. Anti-Infec. Ther. 14(1):125-35.

Mugittu K, Genton B, Mshinda H, Beck HP (2006). Molecular monitoring of Plasmodium falciparum resistance to artemisinin in Tanzania. Malar. J. 5:126.
Crossref

Mwai L, Kiara SM, Abdirahman A, Pole L, Rippert A, Diriye A, Bull P, Marsh K, Borrmann S, Nzila A (2009). In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob. Agents Chemother. 53(12):5069-5073.
Crossref

Ndounga M, Mayengue PI, Casimiro PN, Loumouamou D, Basco LK, Ntoumi F, Brasseur P (2013). Artesunate-amodiaquine efficacy in Congolese children with acute uncomplicated falciparum malaria in Brazzaville. Malar. J. 12(1):53.
Crossref

Nhama A, Bassat Q, Enosse S, Nhacolo A, Mutemba R, Carvalho E, Naueia E, Sevene E, Guinovart C, Warsame M, Sanz S, Mussa A, Matsinhe G, Alonso P, Tiago A, Macete E (2014). In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated falciparum malaria in children: a multisite, open-label, two-cohort, clinical trial in Mozambique. Malar. J. 13:309.
Crossref

Njokah MJ, Kang'ethe JN, Kinyua J, Kariuki D, Kimani FT (2016). In vitro selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemisinin. Malar. J. 15(1):381.
Crossref

Noedl H, Attlmayr B, Wernsdorfer WH, Kollaritsch H, Miller RS (2004). A histidine-rich protein 2-based malaria drug sensitivity assay for field use. Am. J. Trop. Med. Hyg. 71(6):711-714.

Noedl H, Bronnert J, Yingyuen K, Attlmayr B, Kollaritsch H, Fukuda M (2005). Simple histidine-rich protein 2 double-site sandwich enzyme-linked immunosorbent assay for use in malaria drug sensitivity testing. Antimicrob. Agents Chemother. 49(8):3575-3577.
Crossref

Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM (2008). Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 359(24):2619-20.
Crossref

Noedl H, Wernsdorfer WH, Miller RS, Wongsrichanalai C (2002). Histidine-rich protein II: A novel approach to malaria drug sensitivity testing. Antimicrob. Agents Chemother. 46(6):1658-1664.
Crossref

Pascual A, Parola P, Benoit-Vical F, Simon F, Malvy D, Picot S, Delaunay P, Basset D, Maubon D, Faugère B, Ménard G, Bourgeois N, Oeuvray C, Didillon E, Rogier C, Pradines B (2012). Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum. Malar. J. 11(1):45.
Crossref

Pradines B, Bertaux L, Pomares C, Delaunay P, Marty P (2011). Reduced in vitro susceptibility to artemisinin derivatives associated with multi-resistance in a traveller returning from South-East Asia. Malar. J. 10:268.
Crossref

Pradines B, Tall A, Parzy D, Spiegel A, Fusai T, Hienne R, Trape JF, Doury JC (1998). In-vitro activity of pyronaridine and amodiaquine against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial agents. J. Antimicrob. Chemother. 42(3):333-339.
Crossref

Price RN, Marfurt J, Chalfein F, Kenangalem E, Piera KA, Tjitra E, Anstey NM, Russell B (2010). In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax. Antimicrob. Agents Chemother. 54(12):5146-5150.
Crossref

Price RN, Nosten F, Luxemburger C, Van Vugt M, Phaipun L, Chongsuphajaisiddhi T, White NJ (1997). Artesunate/mefloquine treatment of multi-drug resistant falciparum mala